Skip to main content

Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

The Original Article was published on 03 February 2015

Erratum to: SpringerPlus (2015) 4:54 DOI 10.1186/s40064-015-0827-8

It has come to our attention that during production of the original article, some of the column headings were missing from Tables 1 and 2. The corrected Tables 1 and 2 can be found below. The publisher apologises for any inconvenience caused.

Table 1 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents prior to generic availability
Table 2 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents before and after availability of generic alternatives

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ann Butler Nattinger.

Additional information

The online version of the original article can be found under doi:10.1186/s40064-015-0827-8.

Rights and permissions

Open access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nattinger, A.B., Pezzin, L.E., McGinley, E.L. et al. Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. SpringerPlus 4, 531 (2015). https://doi.org/10.1186/s40064-015-1233-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s40064-015-1233-y